Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled trial of pirfenidone in unclassifiable progressive fibrosing interstitial lung disease
MOH_2017-06-07_000445Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in unclassifiable progressive fibrosing interstitial lung disease comparing Pirfenidone with Placebo (2 arms). Primary endpoint: Rate of decline in forced vital capacity. Started Apr 2017; status: active, not recruiting.
02
Drugs
pirfenidone
03
Conditions
unclassifiable progressive fibrosing interstitial lung disease
Beyond the preview
Go deeper on MOH_2017-06-07_000445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-07_000445.